InvestorsHub Logo
icon url

HDGabor

05/21/14 7:04 AM

#27958 RE: RobinF #27955

We have to be down to earth. No BO till (and no guarantee after that):

- 30k script / week (It will be higher than now, but KOWA effect will be reflected in the data for 2nd / 3rd week of June only and as it’s the start I do not expect significant increase (just later))

and / or

- ANCHOR approval (or buyer's agreement w FDA in the background for approval)

and / or

- announcement of 967 event in R-IT (not the result/analysis) not earlier than March 2016 (if it will be earlier it means that eff. is less than 25%)
icon url

BioChica

05/21/14 8:31 AM

#27961 RE: RobinF #27955

I think it boils down to large doses of EPA rather than DHA, is where the science is headed!
icon url

Nukemtiltheyglow

05/21/14 9:09 AM

#27962 RE: RobinF #27955

Robin, it shows a sign of AZN weakness which most likely should be used as fodder by Ian Reed to sway AZN shareholders to his point of view. Very poor execution by Soriot to buy Omthera to begin with. Question is; how will Soriot explain this one? Reed is no dummy. Look for more news coming. P wants AZN in a bad way.